International Federation of Pharmaceutical Manufacturers & Associations

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.¹⁾

Members of the IFPMA include:²⁾

Access Accelerated unites the efforts of 20+ member companies and five implementing partners to drive sustainable solutions at scale for non-communicable diseases (NCD). Local priorities and the meaningful input of people living with NCDs guide our efforts to deliver on our vision of a future where all people have access to quality NCD prevention, treatment and care.³⁾

The concept of the AMR Action Fund was developed by the IFPMA and the Biopharmaceutical CEOs Roundtable (BCR), and biopharmaceutical companies and foundation, in collaboration with the World Health Organization (WHO), the European Investment Bank (EIB), and the Wellcome Trust.⁴⁾

The AMR Industry Alliance brings together over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations, to drive and measure the life-sciences’ industry progress to curb antimicrobial resistance.⁵⁾

The Business Ethics for Asia-Pacific Economic Cooperation (APEC) SMEs Initiative launched the biopharmaceutical sector programme in September 2011, with the aim of disseminating high-standard ethical business practices across 21 leading Asia-Pacific economies across four continents. The mission is to “facilitate a level playing field for all biopharmaceutical enterprises while supporting small and medium-sized enterprises, reduce reputational and legal risk for the sector, and build trust through ethics among key stakeholders across economies’ health systems.”⁶⁾

The H3D Foundation was established in 2019 to create an absorptive capacity for securing, building and retaining skilled African scientists within innovative R&D.^{7) 8)}

The Global Innovative Health Industries Alliance (GIHIA) is a collaborative platform for international associations representing biopharmaceuticals, biotech, diagnostics, medical devices, and diagnostic imaging industries to foster dialogue & collaboration for innovation.⁹⁾ The 4 founding members of the Alliance are:

• International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
• International Council of Biotechnology Associations (ICBA)
• Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade Association (DITTA)
• Global Self-Care Federation (GSCF)

Youth Perspectives. EmpoweRed (HYPER) is a platform serving to mobilize, equip, and connect young representatives in the life-science industry. HYPER increases young professionals' exposure to global health issues. By doing so, it leverages and reinforces the culture of networking and enables young professionals to share their stories and learn from each other. HYPER provides transformative learning experiences that build the capacity of young people to lead change in public health and sustainability.^{10) 11)}

The Patent Information Initiative for Medicines (Pat-INFORMED) is a unique resource where patent holders provide information about patents covering approved medicines through a free, open access database. A private-public partnership between the World Intellectual Property Organisation (WIPO), the specialized UN agency, and the research-based pharmaceutical industry, is a practical step in helping to reduce the complexity surrounding patent information and make it easier for procurement experts to search the patent status of medicines.¹²⁾

The primary target of the #TogetherAgainstFlu initiative is to encourage people at risk of flu complications to get vaccinated, thus avoiding further burden on the health care system, especially during the COVID-19 pandemic.¹³⁾

The International Federation of Red Cross and Red Crescent Societies (IFRC) and the IFPMA engaged in a partnership “which provides information and tools to change behaviours, promote healthy lifestyles in communities around the world and ultimately to reduce the rise of NCDs.”¹⁴⁾

The Africa Young Innovators for Health Award is a joint flagship program between the IFPMA and Speak Up Africa, focused on supporting pioneering young health entrepreneurs across Africa with financial and in-kind opportunities to develop their business ideas. And also advance promising solutions to support, equip, protect, and train healthcare workers who have been working tirelessly to protect and treat the public amidst the COVID-19 pandemic.¹⁵⁾

Global Health Progress is an interactive resource hub highlighting collaborations between the biopharmaceutical industry and various partners to support the Sustainable Development Goals set forth by the United Nations.^{16) 17)}

PAHO Foundation and IFPMA “join forces to strengthen prevention capacity for breast and cervical cancer, as well as to support national cancer policies and planning with the improved collection of reliable data.”¹⁸⁾

Others to add:

• IAEA’s Programme of Action for Cancer Therapy (PACT) Partners with IFPMA on Comprehensive Cancer Control
• The AFRO Comprehensive Cervical Cancer Prevention and Control Initiative
• Be Healthy Be Mobile
• PAHO Foundation Project for Mobilizing and Facilitating Multi-Sector Support of AMR Control in LAC
• HealthyScore
• Let Kids be Kids
• Fight The Fakes
• Consensus Framework for Ethical Collaboration
• Protecting the Integrity of Science and Sport

(Wayback capture 1998) The members of IFPMA are national pharmaceutical industry associations in 56 countries in both the industrialised and developing countries. Member Associations are in direct membership of the Federation except in the case of the Latin American countries, which belong through the regional organisation, Federación Latinamericana de la Industria Farmacéutica (FIFARMA). The pharmaceutical industry represented by IFPMA, through its Member Associations, includes small and medium-sized manufacturers of prescription medicines, as well as the multinational research-based industry.

The conditions for membership of the Federation include commitments by the association, on behalf of its members to good manufacturing practices and acceptance of the provisions of the IFPMA Code of Pharmaceutical Marketing Practices.

IFPMA has a close working relationship with the European Federation of Pharmaceutical Industry Associations (EFPIA), Brussels, and EFPIA's sixteen Member Associations are also members of IFPMA but the two federations are completely separate administrations. EFPIA deals with all matters concerning the relationship between the pharmaceutical industry and the Commission of the European Communities and the EC Directives which are concerned with prescription medicines.

The associations in the Latin American region (*) are affiliated to IFPMA through their membership of Federación Latinoamericana de la Industria Farmacéutica - FIFARMA, which has its executive office in Venezuela (address as for CAVEME above).

List updated November 1997 ¹⁹⁾

• National Associations
• Australia France Italy Norway Sri Lanka
• Austria Germany Japan The Phillipines Sweden
• Belgium Greece Kenya Poland Switzerland
• Brazil Hong Kong Korea Portugal Thailand
• Canada India Malaysia Russia Turkey
• Czech Republic Indonesia Morocco Singapore United Kingdom
• Denmark Ireland The Netherlands South Africa United States of America
• Finland Israel New Zealand Spain
• ²⁰⁾

USA - Pharmaceutical Research and Manufacturers of America - PhRMA 1100 Fifteenth Street NW Washington D. C. 20005

Pharmaceutical Research and Manufacturers of America, also known as PhRMA, is one of the largest and most influential lobbying organizations in Washington. Representing 48 pharmaceutical companies, PhRMA has 20 registered lobbyists on staff[ and has contracted with dozens of lobby and PR firms – including Akin, Gump, Strauss, Hauer & Feld, Barbour Griffith & Rogers, DCI Group and The Dutko Group– to promote its members' interests. PhRMA has a record of hiding its lobbying and PR activities, often by paying other organizations, such as United Seniors Association (USA) or the Consumer Alliance, to advocate industry-friendly policies.

PhRMA was a member of ALEC's “Private Enterprise” Board of Directors as of 2016, with lobbyist Jeff Bond representing it on the board.ALEC is a corporate bill mill. It is not just a lobby or a front group; it is much more powerful than that. Through ALEC, corporations hand state legislators their wishlists to benefit their bottom line. Corporations fund almost all of ALEC's operations. They pay for a seat on ALEC task forces where corporate lobbyists and special interest reps vote with elected officials to approve “model” bills. Learn more at the Center for Media and Democracy's ALECexposed.org, and check out breaking news on our

In May 2005, former member of Congress Billy Tauzin, then PhRMA's head lobbyist, told the New York Times that “drug companies [are] trying to develop a voluntary code of conduct for the advertising of prescription medicines on television and in print.” Tauzin said “a good strong code” would likely be issued in June or July 2005. However, “one purpose” for the code “is to fend off more stringent federal regulation,” wrote the New York Times.

In the early 1990s, the pharmaceutical industry began paying the FDA millions of dollars in user fees in order to speed up the drug approval process. These fees “now fund more than half the agency's critical drug-review process.” Industry groups and the FDA renegotiate the fees and how they're used every five years, giving drug makers “considerable input into which programs receive funding.” In 2006 the FDA negotiated an agreement with the Pharmaceutical Research and Manufacturers of America and Biotechnology Industry Organization. Industry groups pushed for even faster decisions on labeling and other “conditions” of new drugs and the FDA negotiated more funding to monitor drug safety following approval

PhRMA lobbying activities have extended outside of the United States. “America's big drug companies are intensifying their lobbying efforts to 'change the Canadian health-care system' and eliminate subsidized prescription drug prices enjoyed by Canadians,” CanWest News Service reported on June 9, 2003. “A prescription drug industry spokesman in Washington confirmed to CanWest News Service that information contained in confidential industry documents is accurate and that $1 million US is being added to the already heavily funded drug lobby against the Canadian system.” PhRMA was the leading drug industry trade group behind the increased lobbying and PR campaign. PhRMA was also independently spending $450,000 to target the booming Canadian Internet pharmacy industry, which has been providing Americans with prescription drugs at lower prices than in the United States.²¹⁾